Dipraglurant + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Blepharospasm
Conditions
Blepharospasm, Dystonia
Trial Timeline
Oct 6, 2021 → Nov 27, 2022
NCT ID
NCT05027997About Dipraglurant + Placebo
Dipraglurant + Placebo is a phase 2 stage product being developed by Addex Therapeutics for Blepharospasm. The current trial status is completed. This product is registered under clinical trial identifier NCT05027997. Target conditions include Blepharospasm, Dystonia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05027997 | Phase 2 | Completed |
| NCT04857359 | Phase 2/3 | Terminated |
Competing Products
2 competing products in Blepharospasm
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Botulinum toxin type A | Ipsen | Phase 2 | 49 |
| Korean Botulinum toxin type A (KbtxA) and Botox injection | Pacific Biosciences | Phase 3 | 69 |